-
1.发明授权公开(公告)号：US09850283B2
公开(公告)日：2017-12-26
申请号：US15009575
申请日：2016-01-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
IPC: C07K7/56 , A61K38/12 , C07K7/08 , G01N33/68 , A61K38/10 , A61K39/39 , A61K45/06 , G01N33/574 , A61K38/00
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
2.发明申请MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS 有权PD-1 / PD-L1和CD80（B7-1）/ PD-L1蛋白/蛋白质相互作用的MACROCYCLIC抑制剂公开(公告)号：US20140294898A1
公开(公告)日：2014-10-02
申请号：US14201977
申请日：2014-03-10
Applicant: Bristol-Myers Squibb Company
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Abstract translation: 本公开提供了抑制PD-1 / PD-L1和PD-L1 / CD80蛋白/蛋白相互作用的新型大环肽，因此可用于改善各种疾病，包括癌症和感染性疾病。
-
Patent Agency Ranking
3.发明申请公开(公告)号：US20170369530A1
公开(公告)日：2017-12-28
申请号：US15672526
申请日：2017-08-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
4.发明申请MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS 审中-公开PD-1 / PD-L1和CD80（B7-1）/ PD-L1蛋白/蛋白质相互作用的MACROCYCLIC抑制剂公开(公告)号：US20160158349A1
公开(公告)日：2016-06-09
申请号：US15009575
申请日：2016-01-28
Applicant: Bristol-Myers Squibb Company
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Abstract translation: 本公开提供了抑制PD-1 / PD-L1和PD-L1 / CD80蛋白/蛋白相互作用的新型大环肽，因此可用于改善各种疾病，包括癌症和感染性疾病。
-
5.发明授权公开(公告)号：US10538555B2
公开(公告)日：2020-01-21
申请号：US15510138
申请日：2014-09-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Kevin W. Gillman , Qian Zhao , Katharine A. Grant-Young , Paul Michael Scola , Lyndon A. M. Cornelius
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
6.发明申请公开(公告)号：US20170260237A1
公开(公告)日：2017-09-14
申请号：US15510138
申请日：2014-09-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Kevin W. Gillman , Qian Zhao , Katharine A. Grant-Young , Paul Michael Scola , Lyndon A.M. Cornelius
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
7.发明授权Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions 有权PD-1 / PD-L1和CD80（B7-1）/ PD-L1蛋白/蛋白相互作用的大环抑制剂公开(公告)号：US09308236B2
公开(公告)日：2016-04-12
申请号：US14201977
申请日：2014-03-10
Applicant: Bristol-Myers Squibb Company
Inventor： Michael Matthew Miller , Claudio Mapelli , Martin Patrick Allen , Michael S. Bowsher , Kenneth M. Boy , Eric P. Gillis , David R. Langley , Eric Mull , Maude A. Poirier , Nishith Sanghvi , Li-Qiang Sun , Daniel J. Tenney , Kap-Sun Yeung , Juliang Zhu , Patrick C. Reid , Paul Michael Scola
IPC: C07K7/56 , A61K38/12 , C07K7/08 , G01N33/68 , A61K38/10 , A61K39/39 , A61K45/06 , G01N33/574 , A61K38/00
CPC classification number: C07K7/56 , A61K38/00 , A61K38/10 , A61K39/39 , A61K45/06 , C07K7/08 , G01N33/574 , G01N2333/70532 , G01N2500/02 , G01N2800/26 , Y02A50/463
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Abstract translation: 本公开提供了抑制PD-1 / PD-L1和PD-L1 / CD80蛋白/蛋白相互作用的新型大环肽，因此可用于改善各种疾病，包括癌症和感染性疾病。
-
-
-
-
-
-
Search Results
7
records
(took 0.062 seconds)
